Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Second quarter total revenue of $166 million,Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million

Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million

UX143 for osteogenesis imperfecta Phase 3 data from Orbit and Cosmic studies expected around the end of the year

GTX-102 for Angelman syndrome received Breakthrough Therapy Designation from FDA;Phase 3 Aspire study fully enrolled

NOVATO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended June 30, 2025.

"In the first half of the year, we delivered 20% revenue growth from our commercial therapies versus the prior year. We are continuing along our path to profitability in 2027, as we drive our top line growth and maintain our fiscal discipline," said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. "We are excited for the potential of UX143 in osteogenesis imperfecta to reduce fractures and meaningfully improve patients' bone health and for GTX-102 in Angelman syndrome to transform the lives of patients and their families affected by this neurodevelopment disease."

Second Quarter 2025 Selected Financial Data Tables and Financial Results

Revenues (dollars in thousands), (unaudited)

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Crysvita

 

 

 

 

 

 

 

 

Product sales, Latin America and Türkiye

 

$

34,727

 

 

$

40,449

 

 

$

89,807

 

 

$

76,690

 

Royalty revenue – U.S. and Canada

 

 

79,083

 

 

 

67,045

 

 

 

119,936

 

 

 

107,447

 

Royalty revenue – Europe

 

 

6,596

 

 

 

6,176

 

 

 

13,528

 

 

 

12,118

 

Total Crysvita Revenue

 

 

120,406

 

 

 

113,670

 

 

 

223,271

 

 

 

196,255

 

Dojolvi

 

 

23,207

 

 

 

19,355

 

 

 

40,216

 

 

 

35,717

 

Evkeeza

 

 

14,573

 

 

 

7,856

 

 

 

25,604

 

 

 

11,131

 

Mepsevii

 

 

8,310

 

 

 

6,145

 

 

 

16,697

 

 

 

12,756

 

Total revenues

 

$

166,496

 

 

$

147,026

 

 

$

305,788

 

 

$

255,859

 

Total RevenuesUltragenyx reported $166 million in total revenue for the second quarter of 2025, which represents 13% growth compared to the same period in 2024. Second quarter 2025 Crysvita revenue was $120 million, which includes product sales of $35 million from Latin America and Türkiye. Dojolvi revenue in the second quarter 2025 was $23 million. Evkeeza revenue in the second quarter 2025 was $15 million as we continue to launch in the Ultragenyx territories outside of the United States.

Selected Financial Data (dollars in thousands, except per share amounts), (unaudited)

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Total revenues

 

$

166,496

 

 

$

147,026

 

 

$

305,788

 

 

$

255,859

 

Operating expenses:

 

 

 

 

 

 

 

 

Cost of sales

 

 

23,002

 

 

 

21,280

 

 

 

51,664

 

 

 

38,813

 

Research and development

 

 

164,736

 

 

 

161,503

 

 

 

330,508

 

 

 

339,990

 

Selling, general and administrative

 

 

86,646

 

 

 

80,604